🎈 Up Big Today: Find today's biggest gainers with our free screenerTry Stock Screener

Eli Lilly stock target cut, maintains Buy on recent performance

EditorNatashya Angelica
Published 31-10-2024, 08:20 pm
© Reuters.
LLY
-

On Thursday, Truist Securities adjusted its stock price target for Eli Lilly (NYSE:LLY) shares, bringing it down slightly to $1,029 from the previous $1,033 while still maintaining a Buy rating on the stock. The adjustment follows the company's recent performance and market dynamics.

The firm's analyst pointed to the sustained demand for treatments for type 2 diabetes (T2D) and obesity as a key driver for Eli Lilly's growth. The analyst believes that the current market weakness presents an opportunity for investors to buy into the stock. This optimism is based on positive quarter-over-quarter prescription growth and management's confidence that this trend could continue into the fourth quarter.

Eli Lilly is also expected to benefit from international launches slated for the fourth quarter, which are anticipated to bolster sales outside the United States. Moreover, there are plans to increase direct-to-consumer (DTC) marketing efforts to reach more patients.

The analyst highlighted the fact that the obesity market penetration is still at a low single-digit level, approximately 4-5%, and with Eli Lilly's treatment TZP projected to reach sales of around $12 to $13 billion in the fiscal year 2024, there remains a significant market opportunity. The total addressable market for these treatments is estimated to be well over $100 billion, which also bodes well for related products in the pharmaceutical sector.

In summary, Truist Securities reaffirms its Buy rating for Eli Lilly with a revised price target of $1,029, down from $1,033, citing the company's potential for substantial growth in the T2D and obesity markets.

In other recent news, Eli Lilly has reported significant growth in its third-quarter earnings, with a notable 42% increase in revenue. This growth was largely driven by sales of its diabetes and cancer drugs, Mounjaro and Zepbound, which surpassed $3 billion. The company's earnings per share also increased to $1.18 from $0.10 in the same quarter the previous year.

Eli Lilly has raised its revenue guidance for 2024 to between $45.4 billion and $46 billion, expecting a 50% growth in the fourth quarter. Its strategic investments, including $2 billion in Ireland and $4.5 billion for the Lilly Medicine Foundry in Indiana, have been instrumental in its continued expansion.

Key pipeline achievements included new U.S. approvals for Ebglyss and Kisunla and positive study data for tirzepatide and donanemab. Despite facing some physical and financial constraints affecting customer service levels, Eli Lilly remains confident in its growth trajectory and robust pipeline progress. These recent developments indicate a strong performance and strategic positioning for future growth.

InvestingPro Insights

Eli Lilly's strong market position and growth potential, as highlighted in the article, are further supported by recent InvestingPro data.

The company's revenue growth of 31.87% over the last twelve months and an impressive 35.98% growth in the most recent quarter underscore its robust performance in the pharmaceutical sector. This aligns with the analyst's positive outlook on Eli Lilly's growth prospects, particularly in the diabetes and obesity treatment markets.

InvestingPro Tips reveal that Eli Lilly has raised its dividend for 10 consecutive years and has maintained dividend payments for 54 consecutive years, demonstrating a commitment to shareholder returns. This consistency in dividend growth could be particularly attractive to investors looking for stable income alongside potential capital appreciation.

The company's high return over the last year and decade, as noted in the InvestingPro Tips, further supports the analyst's Buy rating. However, it is worth noting that Eli Lilly is trading at high valuation multiples across various metrics, which investors should consider in their decision-making process.

For those seeking a more comprehensive analysis, InvestingPro offers 18 additional tips for Eli Lilly, providing a deeper understanding of the company's financial health and market position.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.